e-Article
A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
Document Type
Abstract
Author
Stein, Eytan; Cai, Sheng F; Huang, Ying ; Dunbar, Andrew; Baer, Maria R.; Stock, Wendy; Kovacsovics, Tibor; Blum, William G.; Schiller, Gary J.; Olin, Rebecca L.; Foran, James M.; Litzow, Mark R.; Lin, Tara L.; Patel, Prapti A. ; Foster, Matthew C.; Boyiadzis, Michael M.; Collins, Robert H.; Chervin, Jordan ; Shoben, Abigail B. ; Vergilio, Jo-Anne ; Heerema, Nyla A.; Rosenberg, Leonard ; Chen, Timothy ; Yocum, Ashley O. ; Druggan, Franchesca ; Marcus, Sonja ; Stefanos, Mona ; Martycz, Molly ; Druker, Brian J.; Mims, Alice S.; Borate, Uma; Burd, Amy; Byrd, John C.; Levine, Ross L.
Source
In Blood 15 November 2022 140 Supplement 1:2016-2019
Subject
Language
ISSN
0006-4971